

Enc 8 Appx 3

Clinical Expert Summary

Perampanel (Fycompa[®]▼) for the adjunctive treatment of partial-onset seizures with or without secondarily generalised seizures in patients with epilepsy aged 12 years and older.

1. Existing guidelines

Experts did not highlight any Welsh specific guidelines. Reference was made to the Managed Clinical Network for Epilepsy in Wales group that disseminates information across Wales and optimises adherence to national guidelines regarding epilepsy management.

2. Disease prevalence/incidence

It was stated that 20–30% of patients with epilepsy continue to have seizures despite receiving anti-epileptic drugs (AEDs). This would equate to approximately 5,000 patients in Wales with uncontrolled epilepsy. One expert estimated that there would be approximately 30–50 patients who would be eligible to receive treatment within their catchment area.

3. Current treatment options

Treatment options in line with National Institute for Health and Care Excellence (NICE) guidance were described. It was stated by one expert that levetiracetam was their preferred adjunctive therapy and is the most widely used.

4. Unmet needs

It was suggested that new AEDs with novel mechanisms of action (such as perampanel) may offer some hope of improvement in patients with epilepsy who continue to experience seizures with current available therapy. The probability of a patient achieving complete freedom from seizure when starting a new AED is approximately 5%, however approximately 30% of patients see some improvement, enhancing personal safety and quality of life.

5. Knowledge of product in given indication

Experts commented that it was not possible to identify patient subgroups where a beneficial response to perampanel could be predicted. The accepted approach is to try a number of options, using medicines with different mechanisms of action. Perampanel's novel mode of action involving antagonism of the AMPA receptor was highlighted as an advantage. One expert stated that perampanel would be used after current AEDs had failed.

It should be noted that experts involved in compiling this response declared a personal specific interest or a personal non-specific interest in relation to perampanel for the indication under consideration.